About Isis
Pioneering antisense drug discovery
We are the leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.
With our efficient antisense drug discovery platform, we can discover many more drugs than we can develop ourselves. We license our drugs to partners prior to late-phase development and commercialization, eliminating the costs associated with a sales and marketing force. This strategy places our drugs in the hands of focused partners who have the expertise and resources to advance our drugs. In addition, we benefit from upfront license fees, milestone payments and royalties as our partners license and develop our drugs. Since 2007, our partnerships have generated an aggregate of more than $840 million in payments from licensing fees, equity purchase payments, milestone payments and research and development funding. In addition, for our current partnered drugs we have the potential to earn more than $3.5 billion in future milestone payments. We also will share in the future commercial success of our inventions and drugs resulting from these partnerships through earn out, profit sharing, and/or royalty arrangements.
Furthermore, as an innovator in RNA-based drug discovery and development, we have designed and executed a patent strategy that has provided us with strong and extensive protection for our drugs as well as all aspects of antisense drug discovery, development and manufacturing. We are continually making improvements to our drug discovery platform and our drugs and expanding our antisense technology to include new opportunities. We expect to remain the leader in all aspects of antisense technology advancement.
Management
Our founders and leaders share a commitment to finding new drug therapies for patients in need.
Learn More
Board of Directors
Learn more about the industry leaders that make up our Board of Directors.
Learn More
Pipeline
Our pipeline continues to grow with novel therapies in development to treat patients who have significant unmet medical needs.
Learn More